Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Campbell & CO Investment Adviser LLC Acquires Shares of 30,418 Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Analysts
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Aviva PLC Takes $499,000 Position in Stoke Therapeutics, Inc. $STOK
All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer